A Systematic Review of the Cost-Effectiveness of Biologics for the Treatment of Inflammatory Bowel Diseases.

by Saara Huoponen, Marja Blom
Published 2015-01-01

Fluoroquinolone-related adverse events resulting in health service use and costs: A systematic review.

by Laura S M Kuula, Kati M Viljemaa, Janne T Backman, Marja Blom
Published 2019-01-01

The cost-effectiveness of biologics for the treatment of rheumatoid arthritis: a systematic review.

by Jaana T Joensuu, Saara Huoponen, Kalle J Aaltonen, Yrjö T Konttinen, Dan Nordström, Marja Blom
Published 2015-01-01

Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis.

by Kalle J Aaltonen, Liisa M Virkki, Antti Malmivaara, Yrjö T Konttinen, Dan C Nordström, Marja Blom
Published 2012-01-01

A systematic review of cost-sharing strategies used within publicly-funded drug plans in member countries of the organisation for economic co-operation and development.

by Lianne Barnieh, Fiona Clement, Anthony Harris, Marja Blom, Cam Donaldson, Scott Klarenbach, Don Husereau, Diane Lorenzetti, Braden Manns
Published 2014-01-01

Cost-effectiveness of abatacept, tocilizumab and TNF-inhibitors compared with rituximab as second-line biologic drug in rheumatoid arthritis.

by Saara Huoponen, Kalle J Aaltonen, Jaana Viikinkoski, Jarno Rutanen, Heikki Relas, Kirsi Taimen, Kari Puolakka, Dan Nordström, Marja Blom
Published 2019-01-01